CDK4 and cancer: Data indicate that this may be mediated, at least in some of these cancers, by deregulation of multiple alternative mitogenic pathways (for example, HER2, PI3K/AKT, and so on) that can potentiate cyclin D1:CDK4/6 signaling in an ER-independent fashion.